An Open-label, Multicenter, Phase 1/1b Dose Escalation Study Evaluating the Pharmacokinetics, Safety, Tolerability, and Preliminary Efficacy of DCDS0780A, Alone or in Combination With Rituximab, or Obinutuzumab, in Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
Phase of Trial: Phase I
Latest Information Update: 19 May 2017
At a glance
- Drugs DCDS 0780A (Primary) ; Obinutuzumab; Rituximab
- Indications Non-Hodgkin's lymphoma
- Focus Adverse reactions
- Sponsors Roche
- 07 Jun 2017 Biomarkers information updated
- 30 Mar 2017 Planned End Date changed from 1 Oct 2018 to 30 Sep 2019.
- 30 Mar 2017 Planned primary completion date changed from 1 Oct 2018 to 30 Sep 2019.